Drug Profile
EDP 235
Alternative Names: Direct acting antivirals - Enanta Pharamceuticals; EDP-235Latest Information Update: 11 May 2023
Price :
$50
*
At a glance
- Originator Enanta Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus-3C-like-proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 08 May 2023 EDP 235 is available for licensing as of 08 May 2023
- 08 May 2023 Efficacy, safety and pharmacokinetic data from a phase II SPRINT trial in COVID-19 infections released by Enanta pharmaceuticals
- 17 Apr 2023 Pharmacokinetics data from a preclinical study in COVID-2019 infections presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2023)